This inventor holds 16 USPTO granted patents. Top assignee: Pfizer Corporation. Active years: 1986-1992.
Location History:
- Upper Walmer, GB (1991)
- Deal, GB (1986 - 1992)
- Keal, GB (1992)
Company Filing History:
Years Active: 1986-1992
Title: **John E Arrowsmith: A Pioneer in Anti-Arrhythmic Agent Innovations**
Introduction
John E Arrowsmith, based in Deal, GB, is an accomplished inventor with an impressive portfolio of 16 patents. His work primarily focuses on the development of novel anti-arrhythmic agents, which serve crucial roles in the treatment of cardiac arrhythmias. Through his innovative research, Arrowsmith has contributed significantly to the pharmaceutical field.
Latest Patents
Arrowsmith's most recent patents include a series of compounds such as Benzoxazole sulfonamide anti-arrhythmic agents. These compounds feature a unique structure characterized by their benzo-fused heterocyclic groups derived from chemicals like benzofuran, benzothiophene, benzoxazole, and quinoline. These agents have shown promise as highly effective therapies for various cardiac arrhythmias. For instance, compounds such as N-methyl-N-(5 methanesulphonamidobenzofur-2-ylmethyl)-4-methanesulphonamidophenethylamine stand out as preferred variants due to their robust therapeutic properties.
Additionally, Arrowsmith has developed Indane sulfonamide anti-arrhythmic agents, which also employ a benzofused heterocyclic moiety. These novel 5-alkanesulphonamido-2-[N-(alkanesulphonamidoheterocyclicmethyl)-N-methylamino]indane compounds exemplify the innovative approaches Arrowsmith has taken towards advancing anti-arrhythmic therapies. His focus on methods for preparing these compounds from known starting materials demonstrates a commitment to practical applications in drug development.
Career Highlights
Throughout his career, John E Arrowsmith has made significant strides in pharmaceutical research, particularly at Pfizer Corporation, where he continues to contribute his expertise in drug innovation. His 16 patents reflect not only his individual accomplishments but also highlight his dedication to improving patient care through effective medication development.
Collaborations
Collaboration has been key to Arrowsmith's success, and he has worked alongside notable colleagues such as Peter E Cross and Geoffrey N Thomas. Together, they have explored various avenues for creating novel compounds, ultimately enhancing the therapeutic landscape for anti-arrhythmic agents. These partnerships have further solidified his reputation in the industry and facilitated the sharing of innovative ideas.
Conclusion
In conclusion, John E Arrowsmith stands out as a leading inventor in the field of pharmaceutical innovations, particularly in the development of anti-arrhythmic agents. His recent patents showcase the depth of his research and its potential impact on treating cardiac arrhythmias. With a strong foundation at Pfizer Corporation and collaborations with esteemed colleagues, Arrowsmith's work continues to pave the way for advancements in pharmacology and medical treatment.